0001104659-20-112885.txt : 20201007 0001104659-20-112885.hdr.sgml : 20201007 20201007081012 ACCESSION NUMBER: 0001104659-20-112885 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20201007 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20201007 DATE AS OF CHANGE: 20201007 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OCULAR THERAPEUTIX, INC CENTRAL INDEX KEY: 0001393434 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36554 FILM NUMBER: 201228102 BUSINESS ADDRESS: STREET 1: 24 CROSBY DRIVE CITY: BEDFORD STATE: MA ZIP: 01730 BUSINESS PHONE: 781-895-3235 MAIL ADDRESS: STREET 1: 24 CROSBY DRIVE CITY: BEDFORD STATE: MA ZIP: 01730 FORMER COMPANY: FORMER CONFORMED NAME: I-THERAPEUTIX INC DATE OF NAME CHANGE: 20070315 8-K 1 tm2032644d1_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 7, 2020

OCULAR THERAPEUTIX, INC.

(Exact Name of Company as Specified in Charter)

Delaware		001-36554		20-5560161
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

24 Crosby Drive

Bedford, MA 01730

(Address of Principal Executive Offices) (Zip Code)

Company’s telephone number, including area code: (781) 357-4000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		OCUL		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02

Results of Operations and Financial Condition.

On October 7, 2020, Ocular Therapeutix, Inc. (the “Company”) issued a press release (the “Release”) to provide a business update. A copy of the Release is included as Exhibit 99.1 hereto and is incorporated by reference herein.

Although the Company is currently in the process of finalizing its operational and financial results for the quarter ended September 30, 2020 (the “Third Quarter”), the Company disclosed in the Release that it expects to report between $5.8 million and $5.9 million of total net product revenue for the Third Quarter, compared with a total net product revenue of approximately $1.6 million for the quarter ended June 30, 2020 (the “Second Quarter”). The Company expects Third Quarter total net product revenue to be comprised of (i) between $5.3 million and $5.4 million of net product revenue for DEXTENZA^®(dexamethasone ophthalmic insert) 0.4mg, compared with approximately $1.4 million for the Second Quarter, and (ii) approximately $0.5 million of net product revenue for ReSure^® Sealant, compared with approximately $0.2 million for the Second Quarter.

The Company also reported monthly in-market unit sales figures for the Third Quarter of 2,221 billable inserts sold in July; 2,920 billable inserts sold in August; and an estimated 4,812 billable inserts sold in September. In-market sales consist of sales from authorized distributors of Company products to medical centers such as ambulatory surgery centers or hospital outpatient departments.

The estimated net product revenue figures for the Third Quarter discussed above are based on preliminary and unaudited information and management’s estimates as of the date of this Current Report on Form 8-K and are subject to completion of the Company’s financial closing procedures. The Company’s independent registered public accounting firm has not conducted an audit or review of, and does not express an opinion or any other form of assurance with respect to, the estimated net product revenue figures.

The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall be deemed to be “filed” and not “furnished” under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall be deemed to be incorporated by reference in applicable filings under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits:

	99.1*	Press Release of Ocular Therapeutix, Inc., dated October 7, 2020

	104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

	*	Indicates this exhibit shall be deemed filed, and not furnished, herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	OCULAR THERAPEUTIX, INC.


Date: October 7, 2020	By:	/s/ Donald Notman
		Donald Notman
		Chief Financial Officer

EX-99.1 2 tm2032644d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

Ocular Therapeutix Announces Preliminary Net Product Revenue of $5.8 Million to $5.9 Million for Third Quarter 2020, Representing Greater Than a 250% Increase Over the Previous Quarter

BEDFORD, MASS. – (BUSINESS WIRE) – October 7, 2020 – Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported preliminary, unaudited net product revenue for the third quarter ended September 30, 2020.

The Company is reporting preliminary third quarter 2020 total net product revenue of $5.8 to 5.9 million, representing a greater than 250 % sequential increase over the second quarter. Net product revenue of DEXTENZA^® (dexamethasone ophthalmic insert) 0.4mg and ReSure^® Sealant for the quarter ended September 30, 2020, are estimated at $5.3 to 5.4 million and $0.5 million, respectively, reflecting individual product quarterly sequential growth of net product revenue of approximately 280% and 150%, respectively. The Company expects to announce financial results for the third quarter 2020 and to provide a business update on November 5, 2020 and discuss its quarterly results in a conference call following the close of market the same day.

Despite continued impact from the COVID pandemic, the Company had a record quarter of DEXTENZA in-market sales as Ambulatory Surgery Centers (ASCs) and Hospital Out Patient Departments (HOPDs) purchased nearly 10,000 billable inserts during the period. DEXTENZA continues to show a steady and robust rebound with the in-market sales of billable inserts into ASCs and HOPDs of 2,221, 2,920 and approximately 4,812 in July, August and September, respectively. The increases observed in the third quarter 2020 build upon the momentum seen in the prior quarter starting in May and reflect continued increases in surgical volumes as ASCs and HOPDs strive to return to pre-COVID shutdown volumes.

”We are very pleased with the growing interest in DEXTENZA and we are encouraged by the growth in our reported sales,” said Antony Mattessich, President and Chief Executive Officer. “We remain committed to serving patient needs and improving access to DEXTENZA while maintaining a strong focus on the purchase of billable units by ASCs and HOPDs since it reflects true in-market demand. For the quarter, our end-customers purchased almost 10,000 billable units with nearly half of that total coming in September. We are experiencing tremendous momentum, and we believe that there is strong receptivity to the DEXTENZA hands-free value proposition in the COVID environment.”

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix’s first commercial drug product, DEXTENZA^®, is FDA-approved for the treatment of ocular inflammation and pain following ophthalmic surgery. Ocular Therapeutix recently completed a Phase 3 clinical trial evaluating DEXTENZA for the treatment of ocular itching associated with allergic conjunctivitis. The Company’s earlier stage development assets currently in Phase 1 trials include OTX-TIC (travoprost intracameral implant) for the reduction of intraocular pressure in patients with primary open-angle glaucoma and ocular hypertension, OTX-CSI (cyclosporine intracanalicular insert) for the treatment of the signs and symptoms of dry eye disease and OTX-TKI (axitinib intravitreal implant) for the treatment of retinal diseases. Also, Ocular Therapeutix is currently developing OTX-DED (dexamethasone intracanalicular insert) for the treatment of episodic dry eye and, in collaboration with Regeneron, OTX-AFS (aflibercept suprachoroidal injection) for an extended-delivery formulation of aflibercept for the treatment of retinal diseases, and Ocular Therapeutix's first product, ReSure^® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

Forward Looking Statements

Any statements in this press release about future expectations, plans, and prospects for the Company, including the commercialization of DEXTENZA^®, ReSure^® Sealant, or any of the Company’s product candidates; the commercial launch of, and effectiveness of reimbursement codes for, DEXTENZA; the conduct of post-approval studies of DEXTENZA; the development and regulatory status of the Company’s product candidates, such as the Company’s development of and prospects for approvability of DEXTENZA for additional indications including allergic conjunctivitis, OTX-DED for the treatment of episodic dry eye disease, OTX-CSI for the treatment of dry eye disease, OTX-TIC for the treatment of primary open-angle glaucoma and ocular hypertension, OTX-TKI for the treatment of retinal diseases including wet AMD, and OTX-AFS as an extended-delivery formulation of the VEGF trap aflibercept for the treatment of retinal diseases including wet AMD; the ongoing development of the Company’s extended-delivery hydrogel depot technology; the size of potential markets for our product candidates; the potential utility of any of the Company’s product candidates; the potential benefits and future operation of the collaboration with Regeneron Pharmaceuticals, including any potential future payments thereunder; projected net product revenue and unit sales and other financial and operational metrics of DEXTENZA; the expected impact of the COVID-19 pandemic on the Company and its operations; the sufficiency of the Company’s cash resources and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend", "goal," "may", "might," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company’s clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the timing and costs involved in commercializing DEXTENZA, ReSure Sealant or any product candidate that receives regulatory approval, including the conduct of post-approval studies, the ability to retain regulatory approval of DEXTENZA, ReSure Sealant or any product candidate that receives regulatory approval, the ability to maintain reimbursement codes for DEXTENZA, the initiation, timing and conduct of clinical trials, availability of data from clinical trials and expectations for regulatory submissions and approvals, the Company’s scientific approach and general development progress, the availability or commercial potential of the Company’s product candidates, the Company’s ability to generate its projected net product revenue and unit sales on the timeline expected, if at all, the sufficiency of cash resources, the Company’s existing indebtedness, the ability of the Company’s creditors to accelerate the maturity of such indebtedness upon the occurrence of certain events of default, the outcome of the Company’s ongoing legal proceedings, the severity and duration of the COVID-19 pandemic including its effect on the Company’s and relevant regulatory authorities’ operations, the need for additional financing or other actions and other factors discussed in the “Risk Factors” section contained in the Company’s quarterly and annual reports on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date of this press release. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so except as required by law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.

Investors

Ocular Therapeutix
Donald Notman
Chief Financial Officer
dnotman@ocutx.com

or

Westwicke, an ICR Company
Chris Brinzey, 339-970-2843
Managing Director

chris.brinzey@westwicke.com

Media
Ocular Therapeutix
Scott Corning
Senior Vice President, Commercial
scorning@ocutx.com

EX-101.SCH 3 ocul-20201007.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 ocul-20201007_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 ocul-20201007_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 tm2032644d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001393434 2020-10-07 2020-10-07 iso4217:USD shares iso4217:USD shares 0001393434 false 8-K 2020-10-07 OCULAR THERAPEUTIX, INC. DE 001-36554 20-5560161 24 Crosby Drive Bedford MA 01730 781 357-4000 false false false false Common Stock, $0.0001 par value per share OCUL NASDAQ false XML 7 R1.htm IDEA: XBRL DOCUMENT

Cover	Oct. 07, 2020
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Oct. 07, 2020
Entity File Number	001-36554
Entity Registrant Name	OCULAR THERAPEUTIX, INC.
Entity Central Index Key	0001393434
Entity Tax Identification Number	20-5560161
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	24 Crosby Drive
Entity Address, City or Town	Bedford
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01730
City Area Code	781
Local Phone Number	357-4000
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	OCUL
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://ocutx.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2032644d1_8k.htm ocul-20201007.xsd ocul-20201007_lab.xml ocul-20201007_pre.xml tm2032644d1_ex99-1.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2032644d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tm2032644d1_8k.htm" ] }, "labelLink": { "local": [ "ocul-20201007_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "ocul-20201007_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "ocul-20201007.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ocul", "nsuri": "http://ocutx.com/20201007", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2032644d1_8k.htm", "contextRef": "From2020-10-07to2020-10-07", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://ocutx.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2032644d1_8k.htm", "contextRef": "From2020-10-07to2020-10-07", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 14 0001104659-20-112885-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-20-112885-xbrl.zip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end